[{"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-001", "question": "A 58-year-old man with a history of hypertrophic cardiomyopathy presents with recurrent syncope. Genetic testing reveals a mutation in the MYH7 gene. Echocardiography shows asymmetric septal hypertrophy with a left ventricular outflow tract gradient of 80 mmHg at rest. Despite optimal medical therapy with beta-blockers, he continues to experience symptoms. What is the most appropriate next step in management?", "options": ["Alcohol septal ablation", "Surgical myectomy", "Implantation of a dual-chamber pacemaker", "Addition of disopyramide", "Cardiac resynchronization therapy"], "answer": "D", "answer_index": 3, "explanation": "Addition of disopyramide is the most appropriate next step as it is recommended for symptomatic hypertrophic cardiomyopathy with obstruction refractory to beta-blockers, acting as a negative inotrope to reduce the gradient. Alcohol septal ablation and surgical myectomy are invasive options considered only after failure of medical therapy including disopyramide. Pacemaker implantation and cardiac resynchronization therapy are not first-line for outflow tract obstruction in this context.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - surgical myectomy (B) is the correct best answer, not disopyramide (D). Key stem clues: 58-year-old with HCM, recurrent syncope, severe LVOT gradient (80 mmHg at rest), refractory to optimal beta-blocker therapy. The question asks for \\\"most appropriate next step\\\" after beta-blocker failure. Main logical issue: The keyed answer (D, disopyramide) represents appropriate medical escalation, but the stem explicitly states \\\"despite optimal medical therapy\\\" the patient \\\"continues to experience symptoms.\\\" In HCM management guidelines, disopyramide is added to beta-blockers as medical optimization before invasive therapy. However, surgical myectomy (B) is the gold-standard definitive treatment for symptomatic obstructive HCM refractory to medical therapy, particularly with severe gradients (≥50 mmHg) and recurrent syncope. Alcohol septal ablation (A) is an alternative when surgery is contraindicated. The rationale incorrectly suggests invasive options are considered \\\"only after failure of medical therapy including disopyramide,\\\" but the stem already indicates medical therapy failure. Medical accuracy issue: The teaching point misrepresents guideline-based sequencing for refractory symptomatic obstructive HCM. Minimal fix: Clarify whether disopyramide was already tried, or change key to B (surgical myectomy) for truly refractory disease.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - surgical myectomy (B) is the correct best answer, not disopyramide (D). Key stem clues: 58-year-old with HCM, recurrent syncope, severe LVOT gradient (80 mmHg at rest), refractory to optimal beta-blocker therapy. The question asks for \"most appropriate next step\" after beta-blocker failure. Main logical issue: The keyed answer (D, disopyramide) represents appropriate medical escalation, but the stem explicitly states \"despite optimal medical therapy\" the patient \"continues to experience symptoms.\" In HCM management guidelines, disopyramide is added to beta-blockers as medical optimization before invasive therapy. However, surgical myectomy (B) is the gold-standard definitive treatment for symptomatic obstructive HCM refractory to medical therapy, particularly with severe gradients (≥50 mmHg) and recurrent syncope. Alcohol septal ablation (A) is an alternative when surgery is contraindicated. The rationale incorrectly suggests invasive options are considered \"only after failure of medical therapy including disopyramide,\" but the stem already indicates medical therapy failure. Medical accuracy issue: The teaching point misrepresents guideline-based sequencing for refractory symptomatic obstructive HCM. Minimal fix: Clarify whether disopyramide was already tried, or change key to B (surgical myectomy) for truly refractory disease.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-002", "question": "A 4-year-old boy with a history of recurrent urinary tract infections is found to have vesicoureteral reflux on voiding cystourethrogram. Renal ultrasound shows mild hydronephrosis. Despite prophylactic antibiotics, he develops breakthrough infections. Genetic evaluation reveals a mutation in the PAX2 gene. What is the most likely associated syndrome?", "options": ["Denys-Drash syndrome", "Renal coloboma syndrome", "Branchio-oto-renal syndrome", "Alport syndrome", "Frasier syndrome"], "answer": "B", "answer_index": 1, "explanation": "Renal coloboma syndrome is associated with PAX2 mutations, characterized by renal hypoplasia, vesicoureteral reflux, and optic nerve colobomas. Denys-Drash and Frasier syndromes involve WT1 mutations, while Alport syndrome relates to collagen IV defects. Branchio-oto-renal syndrome is linked to EYA1 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 4-year-old with recurrent UTIs, vesicoureteral reflux, mild hydronephrosis, breakthrough infections despite prophylaxis, and a PAX2 gene mutation. The question asks for the most likely associated syndrome. Key discriminating finding: PAX2 mutation. Renal coloboma syndrome (also called papillorenal syndrome) is definitively caused by PAX2 mutations and presents with renal hypoplasia/dysplasia, vesicoureteral reflux, and optic nerve colobomas—matching the clinical picture. Option B is the unique best answer. Alternative assessment: A (Denys-Drash) involves WT1 mutations causing Wilms tumor, nephropathy, and genital abnormalities—wrong gene. C (Branchio-oto-renal) involves EYA1/SIX1/SIX5 mutations with branchial, otic, and renal anomalies—wrong gene. D (Alport) involves COL4A3/4/5 mutations causing hereditary nephritis with hearing loss—wrong gene. E (Frasier) involves WT1 mutations with focal segmental glomerulosclerosis and gonadal dysgenesis—wrong gene. The PAX2 mutation is pathognomonic for renal coloboma syndrome, making this a straightforward gene-to-syndrome matching question. Medical accuracy: Excellent. The associations are correct per current genetics literature. No logical flaws or missing details. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 4-year-old with recurrent UTIs, vesicoureteral reflux, mild hydronephrosis, breakthrough infections despite prophylaxis, and a PAX2 gene mutation. The question asks for the most likely associated syndrome. Key discriminating finding: PAX2 mutation. Renal coloboma syndrome (also called papillorenal syndrome) is definitively caused by PAX2 mutations and presents with renal hypoplasia/dysplasia, vesicoureteral reflux, and optic nerve colobomas—matching the clinical picture. Option B is the unique best answer. Alternative assessment: A (Denys-Drash) involves WT1 mutations causing Wilms tumor, nephropathy, and genital abnormalities—wrong gene. C (Branchio-oto-renal) involves EYA1/SIX1/SIX5 mutations with branchial, otic, and renal anomalies—wrong gene. D (Alport) involves COL4A3/4/5 mutations causing hereditary nephritis with hearing loss—wrong gene. E (Frasier) involves WT1 mutations with focal segmental glomerulosclerosis and gonadal dysgenesis—wrong gene. The PAX2 mutation is pathognomonic for renal coloboma syndrome, making this a straightforward gene-to-syndrome matching question. Medical accuracy: Excellent. The associations are correct per current genetics literature. No logical flaws or missing details. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-003", "question": "In the emergency department, a 32-year-old woman presents with acute chest pain and dyspnea following a long-haul flight. CT pulmonary angiography confirms a segmental pulmonary embolism. She has a history of oral contraceptive use and a positive family history for thrombophilia. Laboratory testing shows elevated factor VIII levels. What is the most appropriate initial anticoagulant therapy?", "options": ["Low-molecular-weight heparin followed by warfarin", "Direct oral anticoagulant such as rivaroxaban", "Unfractionated heparin with thrombolysis", "Fondaparinux monotherapy", "Aspirin and clopidogrel combination"], "answer": "B", "answer_index": 1, "explanation": "Direct oral anticoagulants like rivaroxaban are preferred for initial treatment of pulmonary embolism in non-pregnant patients without severe renal impairment or active cancer. Low-molecular-weight heparin followed by warfarin is an alternative but less convenient. Thrombolysis is reserved for hemodynamically unstable cases, and antiplatelet therapy is insufficient for venous thromboembolism.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 32-year-old woman with confirmed segmental PE, risk factors (OCP, family history, elevated factor VIII), but lacks critical discriminating details. Key stem clues: acute PE confirmed by CTPA, recent long-haul flight, OCP use, thrombophilia history. Missing: hemodynamic stability status, renal function, pregnancy status (though OCP use suggests not pregnant), contraindications to specific agents. Main logical issue: Both options A (LMWH→warfarin) and B (rivaroxaban) are equally defensible as initial anticoagulation for acute PE per current guidelines (CHEST, ESC). Modern guidelines favor DOACs for convenience, but LMWH/warfarin remains standard-of-care and equally effective. Without explicit contraindications to warfarin or specific patient preference/compliance concerns stated in the vignette, both are legitimate \\\"best\\\" answers. The rationale dismisses option A as \\\"less convenient\\\" but convenience alone doesn't establish medical superiority for board-exam \\\"best answer\\\" purposes when both are guideline-recommended first-line therapies. Main medical accuracy issue: The explanation conflates convenience with clinical superiority. Minimal fix: Add \\\"patient prefers single-drug regimen\\\" or \\\"no access to INR monitoring\\\" to justify DOAC preference, OR accept both A and B as correct.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 32-year-old woman with confirmed segmental PE, risk factors (OCP, family history, elevated factor VIII), but lacks critical discriminating details. Key stem clues: acute PE confirmed by CTPA, recent long-haul flight, OCP use, thrombophilia history. Missing: hemodynamic stability status, renal function, pregnancy status (though OCP use suggests not pregnant), contraindications to specific agents. Main logical issue: Both options A (LMWH→warfarin) and B (rivaroxaban) are equally defensible as initial anticoagulation for acute PE per current guidelines (CHEST, ESC). Modern guidelines favor DOACs for convenience, but LMWH/warfarin remains standard-of-care and equally effective. Without explicit contraindications to warfarin or specific patient preference/compliance concerns stated in the vignette, both are legitimate \"best\" answers. The rationale dismisses option A as \"less convenient\" but convenience alone doesn't establish medical superiority for board-exam \"best answer\" purposes when both are guideline-recommended first-line therapies. Main medical accuracy issue: The explanation conflates convenience with clinical superiority. Minimal fix: Add \"patient prefers single-drug regimen\" or \"no access to INR monitoring\" to justify DOAC preference, OR accept both A and B as correct.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-004", "question": "A 45-year-old woman presents with symmetric polyarthritis, morning stiffness, and a rash on her trunk. Laboratory tests show positive anti-citrullinated protein antibodies and elevated inflammatory markers. Despite methotrexate therapy, her disease progresses. Genetic testing reveals a mutation in the NLRP3 gene. What is the most likely diagnosis?", "options": ["Rheumatoid arthritis", "Cryopyrin-associated periodic syndrome", "Adult-onset Still's disease", "Behçet's disease", "Systemic lupus erythematosus"], "answer": "B", "answer_index": 1, "explanation": "Cryopyrin-associated periodic syndrome involves NLRP3 mutations, presenting with arthritis, rash, and autoinflammatory features that may mimic rheumatoid arthritis but respond poorly to standard DMARDs. Rheumatoid arthritis typically lacks this genetic mutation and responds to methotrexate. Adult-onset Still's disease and others do not feature NLRP3 mutations.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette presents a patient with symmetric polyarthritis, morning stiffness, positive anti-CCP antibodies, and elevated inflammatory markers—classic features of rheumatoid arthritis (RA). The NLRP3 mutation is then introduced, pointing toward cryopyrin-associated periodic syndrome (CAPS). However, CAPS typically presents with episodic fever, urticarial rash, and systemic inflammation—not symmetric polyarthritis with positive anti-CCP antibodies, which are highly specific for RA. The stem creates an internally contradictory clinical picture: anti-CCP positivity strongly suggests RA (Option A), while NLRP3 mutation suggests CAPS (Option B). Both answers are defensible depending on which finding is prioritized. Medical accuracy issue: CAPS does not typically present with symmetric polyarthritis or anti-CCP positivity; these are RA hallmarks. The vignette conflates two distinct disease entities. Methotrexate failure alone does not exclude RA (many RA patients are MTX-refractory). The explanation incorrectly suggests CAPS mimics RA with these specific features. Minimal fix: Remove anti-CCP positivity and morning stiffness; replace with episodic fever, urticarial rash, and conjunctivitis to make CAPS the clear answer, or remove NLRP3 mutation to make RA unambiguous.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The vignette presents a patient with symmetric polyarthritis, morning stiffness, positive anti-CCP antibodies, and elevated inflammatory markers—classic features of rheumatoid arthritis (RA). The NLRP3 mutation is then introduced, pointing toward cryopyrin-associated periodic syndrome (CAPS). However, CAPS typically presents with episodic fever, urticarial rash, and systemic inflammation—not symmetric polyarthritis with positive anti-CCP antibodies, which are highly specific for RA. The stem creates an internally contradictory clinical picture: anti-CCP positivity strongly suggests RA (Option A), while NLRP3 mutation suggests CAPS (Option B). Both answers are defensible depending on which finding is prioritized. Medical accuracy issue: CAPS does not typically present with symmetric polyarthritis or anti-CCP positivity; these are RA hallmarks. The vignette conflates two distinct disease entities. Methotrexate failure alone does not exclude RA (many RA patients are MTX-refractory). The explanation incorrectly suggests CAPS mimics RA with these specific features. Minimal fix: Remove anti-CCP positivity and morning stiffness; replace with episodic fever, urticarial rash, and conjunctivitis to make CAPS the clear answer, or remove NLRP3 mutation to make RA unambiguous.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-005", "question": "A 28-year-old man with type 1 diabetes mellitus presents with recurrent hypoglycemia despite insulin dose adjustments. Continuous glucose monitoring shows nocturnal hypoglycemia. Laboratory evaluation reveals elevated proinsulin levels and a low C-peptide. What is the most likely underlying mechanism?", "options": ["Insulinoma", "Factitious hypoglycemia from exogenous insulin", "Adrenal insufficiency", "Autoimmune hypoglycemia", "Nesidioblastosis"], "answer": "B", "answer_index": 1, "explanation": "Factitious hypoglycemia from exogenous insulin is indicated by low C-peptide and elevated proinsulin due to suppressed endogenous insulin production. Insulinoma would show high C-peptide and proinsulin. Adrenal insufficiency typically causes hyperglycemia, and autoimmune hypoglycemia involves insulin antibodies with variable C-peptide.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is medically incorrect. The stem describes a type 1 diabetic with recurrent hypoglycemia, elevated proinsulin, and LOW C-peptide. Key discriminating findings: (1) low C-peptide indicates suppressed endogenous insulin production, (2) elevated proinsulin is paradoxical if endogenous production is suppressed. The rationale claims factitious hypoglycemia causes 'elevated proinsulin due to suppressed endogenous insulin production' – this is medically incorrect. Exogenous insulin administration suppresses BOTH C-peptide AND proinsulin (both are endogenous). Low C-peptide with LOW proinsulin would indicate factitious hypoglycemia (option B). However, ELEVATED proinsulin with low C-peptide creates a biochemical contradiction that doesn't fit standard hypoglycemia etiologies. Insulinoma (A) causes elevated C-peptide and proinsulin together. Adrenal insufficiency (C) causes hypoglycemia but not this biochemical pattern. The stem's biochemical profile (high proinsulin + low C-peptide) is internally inconsistent with known pathophysiology. Main medical accuracy issue: the rationale contains a fundamental error about proinsulin behavior in factitious hypoglycemia. Minimal fix: Change laboratory findings to 'low C-peptide and low proinsulin' to make option B correct, or change to 'elevated C-peptide and proinsulin' to make option A correct.\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"C\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is medically incorrect. The stem describes a type 1 diabetic with recurrent hypoglycemia, elevated proinsulin, and LOW C-peptide. Key discriminating findings: (1) low C-peptide indicates suppressed endogenous insulin production, (2) elevated proinsulin is paradoxical if endogenous production is suppressed. The rationale claims factitious hypoglycemia causes 'elevated proinsulin due to suppressed endogenous insulin production' – this is medically incorrect. Exogenous insulin administration suppresses BOTH C-peptide AND proinsulin (both are endogenous). Low C-peptide with LOW proinsulin would indicate factitious hypoglycemia (option B). However, ELEVATED proinsulin with low C-peptide creates a biochemical contradiction that doesn't fit standard hypoglycemia etiologies. Insulinoma (A) causes elevated C-peptide and proinsulin together. Adrenal insufficiency (C) causes hypoglycemia but not this biochemical pattern. The stem's biochemical profile (high proinsulin + low C-peptide) is internally inconsistent with known pathophysiology. Main medical accuracy issue: the rationale contains a fundamental error about proinsulin behavior in factitious hypoglycemia. Minimal fix: Change laboratory findings to 'low C-peptide and low proinsulin' to make option B correct, or change to 'elevated C-peptide and proinsulin' to make option A correct.", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "C", "verdict": "FAIL", "fail_reason": "C"}, "judge_verdict": "FAIL", "judge_fail_reason": "C", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-006", "question": "A 65-year-old man with ischemic cardiomyopathy and an ejection fraction of 25% develops sustained ventricular tachycardia. He is hemodynamically stable. Electrophysiology study identifies a reentrant circuit in the infarct border zone. Despite amiodarone therapy, episodes recur. What is the most appropriate next intervention?", "options": ["Catheter ablation", "Implantable cardioverter-defibrillator upgrade to biventricular", "Addition of mexiletine", "Stellate ganglionectomy", "Cardiac sympathetic denervation"], "answer": "A", "answer_index": 0, "explanation": "Catheter ablation is the most appropriate for recurrent ventricular tachycardia in ischemic cardiomyopathy refractory to antiarrhythmic drugs, targeting the reentrant circuit. ICD upgrade addresses heart failure but not arrhythmia substrate directly. Mexiletine addition is less effective for scar-related VT, and surgical options like ganglionectomy are reserved for refractory cases.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: V. Verdict: Correct best answer. The stem describes a 65-year-old with ischemic cardiomyopathy (EF 25%), sustained VT with identified reentrant circuit in infarct border zone, hemodynamically stable, and recurrent episodes despite amiodarone. Key discriminating findings: (1) structural heart disease with scar-related reentrant VT, (2) drug-refractory (failed amiodarone), (3) hemodynamically stable allowing elective intervention, (4) EP study localizing substrate. The clinical problem asks for next intervention after failed medical therapy. Catheter ablation (A) directly targets the identified reentrant circuit and is guideline-recommended for drug-refractory scar-related VT in ischemic cardiomyopathy. ICD upgrade to CRT (B) addresses heart failure/resynchronization but doesn't eliminate arrhythmia substrate. Mexiletine addition (C) is less effective for scar-related VT and represents another drug trial after amiodarone failure. Stellate ganglionectomy (D) and cardiac sympathetic denervation (E) are reserved for highly refractory cases (electrical storm) after ablation failure. The keyed answer aligns with current guidelines (AHA/ACC/HRS) recommending catheter ablation for recurrent monomorphic VT in structural heart disease refractory to antiarrhythmics. No logical flaws or medical inaccuracies identified. Minimal fix: None needed; item is valid as written.\", \"medical_accuracy_score\": \"5\", \"logical_validity\": true, \"logical_false_reason\": \"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V. Verdict: Correct best answer. The stem describes a 65-year-old with ischemic cardiomyopathy (EF 25%), sustained VT with identified reentrant circuit in infarct border zone, hemodynamically stable, and recurrent episodes despite amiodarone. Key discriminating findings: (1) structural heart disease with scar-related reentrant VT, (2) drug-refractory (failed amiodarone), (3) hemodynamically stable allowing elective intervention, (4) EP study localizing substrate. The clinical problem asks for next intervention after failed medical therapy. Catheter ablation (A) directly targets the identified reentrant circuit and is guideline-recommended for drug-refractory scar-related VT in ischemic cardiomyopathy. ICD upgrade to CRT (B) addresses heart failure/resynchronization but doesn't eliminate arrhythmia substrate. Mexiletine addition (C) is less effective for scar-related VT and represents another drug trial after amiodarone failure. Stellate ganglionectomy (D) and cardiac sympathetic denervation (E) are reserved for highly refractory cases (electrical storm) after ablation failure. The keyed answer aligns with current guidelines (AHA/ACC/HRS) recommending catheter ablation for recurrent monomorphic VT in structural heart disease refractory to antiarrhythmics. No logical flaws or medical inaccuracies identified. Minimal fix: None needed; item is valid as written.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-007", "question": "An 8-year-old girl with short stature and failure to thrive undergoes evaluation. Bone age is delayed, and laboratory tests show low IGF-1 with normal growth hormone stimulation. Genetic testing reveals a mutation in the IGF1R gene. What is the most appropriate management strategy?", "options": ["Recombinant growth hormone therapy", "IGF-1 replacement therapy", "Nutritional supplementation", "Thyroid hormone replacement", "Corticosteroid therapy"], "answer": "B", "answer_index": 1, "explanation": "IGF-1 replacement therapy is indicated for IGF1R mutations causing primary IGF-1 deficiency resistant to growth hormone. Recombinant growth hormone would be ineffective due to receptor defect. Nutritional or hormonal supplements like thyroid or corticosteroids do not address the underlying IGF-1 resistance.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is incorrect. The stem describes an IGF1R gene mutation (IGF-1 receptor defect) with LOW IGF-1 and NORMAL GH stimulation. Key discriminating findings: delayed bone age, low IGF-1, normal GH response, IGF1R mutation. This clinical picture represents primary IGF-1 deficiency due to GH insensitivity (receptor defect), not IGF-1 resistance. The pathophysiology is critical: IGF1R mutations cause resistance to IGF-1 action at the receptor level. Administering exogenous IGF-1 (option B) would be ineffective because the receptor cannot respond properly. Recombinant GH therapy (option A) is the established treatment for GH insensitivity syndromes when the defect lies in GH signaling (e.g., GH receptor mutations, post-receptor defects). However, with an IGF1R mutation, neither GH nor IGF-1 therapy would be effective through normal pathways. The rationale incorrectly states 'primary IGF-1 deficiency resistant to GH' but the vignette shows normal GH stimulation, suggesting adequate GH production. The main medical inaccuracy: IGF-1 replacement cannot overcome an IGF-1 receptor defect. Minimal fix: Clarify whether the mutation causes GH insensitivity (making A correct) or true IGF-1 receptor resistance (making the condition largely untreatable with current options).\", \"medical_accuracy_score\": \"2\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed – the keyed answer is incorrect. The stem describes an IGF1R gene mutation (IGF-1 receptor defect) with LOW IGF-1 and NORMAL GH stimulation. Key discriminating findings: delayed bone age, low IGF-1, normal GH response, IGF1R mutation. This clinical picture represents primary IGF-1 deficiency due to GH insensitivity (receptor defect), not IGF-1 resistance. The pathophysiology is critical: IGF1R mutations cause resistance to IGF-1 action at the receptor level. Administering exogenous IGF-1 (option B) would be ineffective because the receptor cannot respond properly. Recombinant GH therapy (option A) is the established treatment for GH insensitivity syndromes when the defect lies in GH signaling (e.g., GH receptor mutations, post-receptor defects). However, with an IGF1R mutation, neither GH nor IGF-1 therapy would be effective through normal pathways. The rationale incorrectly states 'primary IGF-1 deficiency resistant to GH' but the vignette shows normal GH stimulation, suggesting adequate GH production. The main medical inaccuracy: IGF-1 replacement cannot overcome an IGF-1 receptor defect. Minimal fix: Clarify whether the mutation causes GH insensitivity (making A correct) or true IGF-1 receptor resistance (making the condition largely untreatable with current options).", "medical_accuracy_score": 2, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 2}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-008", "question": "In the emergency department, a 50-year-old man presents with severe abdominal pain and vomiting. CT scan shows acute pancreatitis with necrosis. He develops hypotension and acute kidney injury. Serum triglycerides are 1200 mg/dL. What is the most appropriate initial management for the hypertriglyceridemia?", "options": ["Plasmapheresis", "Insulin infusion", "Fibrates", "Niacin", "Statins"], "answer": "B", "answer_index": 1, "explanation": "Insulin infusion effectively lowers triglycerides in hypertriglyceridemic pancreatitis by enhancing lipoprotein lipase activity. Plasmapheresis is reserved for severe cases not responding to insulin. Fibrates, niacin, and statins are long-term therapies not suitable for acute management.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: K (Miskeyed). Verdict: Miskeyed - plasmapheresis is the correct best answer. The stem describes severe hypertriglyceridemic pancreatitis (TG 1200 mg/dL) with necrotizing pancreatitis, hypotension, and acute kidney injury - indicating critical illness with multi-organ dysfunction. Key discriminating findings: (1) severe hypertriglyceridemia (>1000 mg/dL) causing acute pancreatitis, (2) pancreatic necrosis on CT, (3) hemodynamic instability with AKI. In this critically ill patient with necrotizing pancreatitis and organ failure, plasmapheresis is the most appropriate initial management as it provides rapid triglyceride reduction (50% within hours). While insulin infusion does enhance lipoprotein lipase activity and can lower triglycerides, it works more slowly and is typically used for moderate cases or as adjunct therapy. The presence of necrosis and multi-organ dysfunction makes this a severe case requiring the most aggressive initial intervention. The author's rationale incorrectly states plasmapheresis is 'reserved for severe cases not responding to insulin' - but this IS a severe case at presentation. Medical accuracy issue: The keyed answer reflects outdated or overly conservative management. Current practice favors plasmapheresis as first-line for severe hypertriglyceridemic pancreatitis with organ dysfunction. Minimal fix: Change key to A (Plasmapheresis) or modify stem to remove necrosis/organ failure, making it moderate severity suitable for insulin.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"K\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: K (Miskeyed). Verdict: Miskeyed - plasmapheresis is the correct best answer. The stem describes severe hypertriglyceridemic pancreatitis (TG 1200 mg/dL) with necrotizing pancreatitis, hypotension, and acute kidney injury - indicating critical illness with multi-organ dysfunction. Key discriminating findings: (1) severe hypertriglyceridemia (>1000 mg/dL) causing acute pancreatitis, (2) pancreatic necrosis on CT, (3) hemodynamic instability with AKI. In this critically ill patient with necrotizing pancreatitis and organ failure, plasmapheresis is the most appropriate initial management as it provides rapid triglyceride reduction (50% within hours). While insulin infusion does enhance lipoprotein lipase activity and can lower triglycerides, it works more slowly and is typically used for moderate cases or as adjunct therapy. The presence of necrosis and multi-organ dysfunction makes this a severe case requiring the most aggressive initial intervention. The author's rationale incorrectly states plasmapheresis is 'reserved for severe cases not responding to insulin' - but this IS a severe case at presentation. Medical accuracy issue: The keyed answer reflects outdated or overly conservative management. Current practice favors plasmapheresis as first-line for severe hypertriglyceridemic pancreatitis with organ dysfunction. Minimal fix: Change key to A (Plasmapheresis) or modify stem to remove necrosis/organ failure, making it moderate severity suitable for insulin.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "K", "verdict": "FAIL", "fail_reason": "K"}, "judge_verdict": "FAIL", "judge_fail_reason": "K", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-009", "question": "A 35-year-old woman with seropositive rheumatoid arthritis on infliximab develops fever, weight loss, and lymphadenopathy. Biopsy shows non-caseating granulomas. Serum angiotensin-converting enzyme is elevated. What is the most likely diagnosis?", "options": ["Tuberculosis reactivation", "Infliximab-induced sarcoidosis", "Lymphoma", "Fungal infection", "Amyloidosis"], "answer": "B", "answer_index": 1, "explanation": "Infliximab-induced sarcoidosis is a rare complication of TNF inhibitors, presenting with granulomatous inflammation mimicking sarcoidosis. Tuberculosis would show caseating granulomas and positive cultures. Lymphoma or infections are differentials but less likely without specific evidence.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a patient on infliximab (TNF-α inhibitor) presenting with fever, weight loss, lymphadenopathy, non-caseating granulomas, and elevated ACE. Key discriminating findings: immunosuppression (infliximab), systemic symptoms, non-caseating granulomas, elevated ACE. The keyed answer (B, infliximab-induced sarcoidosis) fits the non-caseating granulomas and elevated ACE pattern. However, option A (TB reactivation) is equally defensible because: (1) TNF-α inhibitors carry high TB reactivation risk—a black-box warning; (2) fever and weight loss are classic TB symptoms; (3) while the explanation states TB shows caseating granulomas, early/atypical TB in immunosuppressed patients can present with non-caseating granulomas; (4) the stem provides no TB screening history or negative cultures to exclude it. The item is underspecified (missing TB screening status, cultures, chest imaging) leading to multiple defensible answers. Medical accuracy issue: the explanation oversimplifies TB presentation in immunosuppressed patients. Drug-induced sarcoidosis is rare; TB reactivation is far more common and dangerous in this population. Minimal fix: add 'negative TB cultures and interferon-gamma release assay' to the stem to exclude TB definitively.\", \"medical_accuracy_score\": \"3\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a patient on infliximab (TNF-α inhibitor) presenting with fever, weight loss, lymphadenopathy, non-caseating granulomas, and elevated ACE. Key discriminating findings: immunosuppression (infliximab), systemic symptoms, non-caseating granulomas, elevated ACE. The keyed answer (B, infliximab-induced sarcoidosis) fits the non-caseating granulomas and elevated ACE pattern. However, option A (TB reactivation) is equally defensible because: (1) TNF-α inhibitors carry high TB reactivation risk—a black-box warning; (2) fever and weight loss are classic TB symptoms; (3) while the explanation states TB shows caseating granulomas, early/atypical TB in immunosuppressed patients can present with non-caseating granulomas; (4) the stem provides no TB screening history or negative cultures to exclude it. The item is underspecified (missing TB screening status, cultures, chest imaging) leading to multiple defensible answers. Medical accuracy issue: the explanation oversimplifies TB presentation in immunosuppressed patients. Drug-induced sarcoidosis is rare; TB reactivation is far more common and dangerous in this population. Minimal fix: add 'negative TB cultures and interferon-gamma release assay' to the stem to exclude TB definitively.", "medical_accuracy_score": 3, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 3}, {"quiz_id": "20251201T041413890Z_grok-4-0709_seed127", "question_id": "20251201T041413890Z_grok-4-0709_seed127-010", "question": "A 42-year-old woman with acromegaly undergoes transsphenoidal surgery, but IGF-1 levels remain elevated postoperatively. She declines further surgery. What is the most appropriate pharmacologic therapy?", "options": ["Cabergoline", "Pegvisomant", "Octreotide", "Pasireotide", "Bromocriptine"], "answer": "B", "answer_index": 1, "explanation": "Pegvisomant, a growth hormone receptor antagonist, is the most effective for normalizing IGF-1 in acromegaly resistant to surgery and somatostatin analogs. Octreotide and pasireotide are somatostatin analogs that may not suffice post-surgery. Dopamine agonists like cabergoline or bromocriptine are less potent for pure GH-secreting adenomas.", "generator_model": "grok-4-0709", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "claude-opus-4-5-20251101", "judge_model_outputs_raw": "{\"analysis\": \"Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 42-year-old woman with persistent IGF-1 elevation after failed transsphenoidal surgery who declines further surgery. The question asks for \\\"most appropriate pharmacologic therapy\\\" but lacks critical information to discriminate between first-line and second-line medical options. Key issue: Standard acromegaly management guidelines recommend somatostatin analogs (octreotide/pasireotide) as first-line medical therapy for persistent disease post-surgery. Pegvisomant is typically reserved for patients who fail or are intolerant to somatostatin analogs. The stem does NOT state that somatostatin analogs have been tried and failed, making both octreotide (C) and pegvisomant (B) defensible. The rationale claims pegvisomant is \\\"most effective\\\" and that somatostatin analogs \\\"may not suffice,\\\" but this assumes prior failure of first-line therapy without stating it. Medical accuracy: The pharmacologic hierarchy is correct (somatostatin analogs first-line, pegvisomant for resistant cases), but the item conflates \\\"most effective\\\" with \\\"most appropriate next step.\\\" Minimal fix: Add \\\"She has been treated with octreotide for 6 months without normalization of IGF-1\\\" to justify pegvisomant as the correct answer.\", \"medical_accuracy_score\": \"4\", \"logical_validity\": false, \"logical_false_reason\": \"M\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: M (Multiple answers defensible). Verdict: Not uniquely determinable. The stem describes a 42-year-old woman with persistent IGF-1 elevation after failed transsphenoidal surgery who declines further surgery. The question asks for \"most appropriate pharmacologic therapy\" but lacks critical information to discriminate between first-line and second-line medical options. Key issue: Standard acromegaly management guidelines recommend somatostatin analogs (octreotide/pasireotide) as first-line medical therapy for persistent disease post-surgery. Pegvisomant is typically reserved for patients who fail or are intolerant to somatostatin analogs. The stem does NOT state that somatostatin analogs have been tried and failed, making both octreotide (C) and pegvisomant (B) defensible. The rationale claims pegvisomant is \"most effective\" and that somatostatin analogs \"may not suffice,\" but this assumes prior failure of first-line therapy without stating it. Medical accuracy: The pharmacologic hierarchy is correct (somatostatin analogs first-line, pegvisomant for resistant cases), but the item conflates \"most effective\" with \"most appropriate next step.\" Minimal fix: Add \"She has been treated with octreotide for 6 months without normalization of IGF-1\" to justify pegvisomant as the correct answer.", "medical_accuracy_score": 4, "logical_validity": false, "logical_false_reason": "M", "verdict": "FAIL", "fail_reason": "M"}, "judge_verdict": "FAIL", "judge_fail_reason": "M", "judge_medical_accuracy_score": 4}]